A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 7, 2014, Pages 935-944

  Magyar, Klara ^a   Deres, Laszlo ^a   Eros, Krisztian ^a   Bruszt, Kitti ^a   Seress, Laszlo ^a   Hamar, Janos ^a   Hideg, Kalman ^a   Balogh, Andras ^a   Gallyas, Ferenc ^a,b   Sumegi, Balazs ^a,b   Toth, Kalman ^a,b   Halmosi, Robert ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

PARP inhibition; Spontaneously hypertensive rat; Vascular remodeling

Indexed keywords

2 [(2 PIPERIDINE 1YLETHYL)THIO]QUINAZOLIN 4(3H) ONE; 2 [2 (1 PIPERIDINYL)ETHYLTHIO] 4(3H) QUINAZOLINONE; COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL WALL; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ELECTRON MICROSCOPY; ELEVATED BLOOD PRESSURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID PEROXIDATION; MALE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR EXPORT SIGNAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT; SUBENDOTHELIUM; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VASCULAR DISEASE; WESTERN BLOTTING;

PARP-INHIBITION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR REMODELING;

ANIMALS; AORTA; BLOOD PRESSURE; CELL DEATH; COLLAGEN; HYPERTENSION; MALE; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RATS; RATS, INBRED SHR; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84897451398     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.03.008     Document Type: Article

References (65)

1. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102:203-210.
2. Deedwania P.C. Blood pressure control in diabetes mellitus: is lower always better, and how low should it go?. Circulation 2011, 123:2776-2778.
3. Qiu C., Winblad B., Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005, 4:487-499.
4. Birns J., Markus H., Kalra L. Blood pressure reduction for vascular risk: is there a price to be paid?. Stroke 2005, 36:1308-1313.
5. Drummond G.R., Selemidis S., Griendling K.K., Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10:453-471.
6. Escobales N., Crespo M.J. Oxidative-nitrosative stress in hypertension. Curr. Vasc. Pharmacol. 2005, 3:231-246.
7. Xie J.J., Yu X., Liao Y.H., Chen J., Yao R., et al. Poly (ADP-Ribose) polymerase inhibition attenuates atherosclerotic plaque development in ApoE-/- mice with hyperhomocysteinemia. J. Atheroscler. Thromb. 2009, 16:641-653.
8. Csiszar A., Pacher P., Kaley G., Ungvari Z. Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. Curr. Vasc. Pharmacol. 2005, 3:285-291.
9. Bendhack L.M., Sharma R.V., Bhalla R.C. Altered signal transduction in vascular smooth muscle cells of spontaneously hypertensive rats. Hypertension 1992, 19:II142-II148.
10. Briones A.M., Touyz R.M. Oxidative stress and hypertension: current concepts. Curr. Hypertens. Rep. 2010, 12:135-142.
11. Montezano A.C., Touyz R.M. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: a basic science update for the clinician. Can. J. Cardiol. 2012, 28:288-295.
12. Wincewicz A., Sulkowska M., Rutkowski R., Sulkowski S., Musiatowicz B., et al. STAT1 and STAT3 as intracellular regulators of vascular remodeling. Eur. J. Intern. Med. 2007, 18:267-271.
13. Castier Y., Ramkhelawon B., Riou S., Tedgui A., Lehoux S. Role of NF-kappaB in flow-induced vascular remodeling. Antioxid. Redox Signal. 2009, 11:1641-1649.
14. Washida K., Ihara M., Nishio K., Fujita Y., Maki T., et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010, 41:1798-1806.
15. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003, 361:2017-2023.
16. Chiu L.Y., Ho F.M., Shiah S.G., Chang Y., Lin W.W. Oxidative stress initiates DNA damager MNNG-induced poly(ADP-ribose)polymerase-1-dependent parthanatos cell death. Biochem. Pharmacol. 2011, 81:459-470.
17. Erdélyi K., Bakondi E., Gergely P., Szabó C., Virág L. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation. Cell. Mol. Life Sci. 2005, 62:751-759.
18. Pacher P., Szabo C. Role of Poly(ADP-ribose)polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 2007, 25:235-260.
19. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., et al. Activation of poly(ADP-ribose)polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 2002, 300:862-867.
20. Halmosi R., Berente Z., Osz E., Toth K., Literati-Nagy P., et al. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol. Pharmacol. 2001, 59:1497-1505.
21. Tapodi A., Debreceni B., Hanto K., Bognar Z., Wittmann I., et al. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J. Biol. Chem. 2005, 28:35767-35775.
22. Wang Y., Dawson V.L., Dawson T.M. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 2009, 218:193-202.
23. Hong S.J., Dawson T.M., Dawson V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. 2004, 25:259-264.
24. Szabó C. Poly (ADP-ribose) polymerase activation and circulatory shock. Novartis Found. Symp. 2007, 280:92-103.
25. Hinz M., Stilmann M., Arslan S.Ç., Khanna K.K., Dittmar G., et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation. Mol. Cell 2010, 40:63-74.
26. Stilmann M., Hinz M., Arslan S.C., Zimmer A., Schreiber V., et al. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol. Cell 2009, 36:365-378.
27. Lemarié C.A., Tharaux P.L., Esposito B., Tedgui A., Lehoux S. Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries. Circ. Res. 2006, 4:434-441.
28. Bartha E., Solti I., Kereskai L., Lantos J., Plozer E., et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc. Res. 2009, 83:501-510.
29. Perrotta I., Brunelli E., Sciangula A., Conforti F., Perrotta E., et al. iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach. Cardiovasc. Pathol. 2011, 20:195-203.
30. Pacher P., Obrosova I.G., Mabley J.G., Szabó C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications, emerging new therapeutical strategies. Curr. Med. Chem. 2005, 12:267-275.
31. Pálfi A., Tóth A., Kulcsár G., Hantó K., Deres P., et al. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J. Pharmacol. Exp. Ther. 2005, 315:273-282.
32. Kulcsar Gy., Kalai T., Osz E., Sar C.P., Jeko J., Sumegi B., Hideg K. Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). ARKIVOC 2003, 121-131.
33. Kubota Y., Umegaki K., Kagota S., Tanaka N., Nakamura K., et al. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol. Pharm. Bull. 2006, 29:1756-1758.
34. Yap S.C., Nemes A., Meijboom F.J., Galema T.W., Geleijnse M.L., et al. Abnormal aortic elastic properties in adults with congenital valvular aortic stenosis. Int. J. Cardiol. 2008, 128:336-341.
35. Radovits T., Seres L., Gero D., Berger I., Szabó C., et al. Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Exp. Gerontol. 2007, 42:676-685.
36. Vincze A., Mázló M., Seress L., Komoly S., Abrahám H. A correlative light and electron microscopic study of postnatal myelination in the murine corpus callosum. Int. J. Dev. Neurosci. 2008, 26:575-584.
37. Multiple risk factor intervention trial research group. Multiple risk factor intervention trial, risk factor changes and mortality results. JAMA 1997, 277:582-594.
38. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
39. Birukov K.G. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid. Redox Signal. 2009, 11:1651-1667.
40. Ali M.H., Mungai P.T., Schumacker P.T. Stretch-induced phosphorylation of focal adhesion kinase in endothelial cells: role of mitochondrial oxidants. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 291:L38-L45.
41. Ali M.H., Schumacker P.T. Endothelial responses to mechanical stress: where is the mechanosensor?. Crit. Care Med. 2002, 30:S198-S206.
42. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 2011, 51:1289-1301.
43. Rey F.E., Cifuentes M.E., Kiarash A., Quinn M.T., Pagano P.J. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ. Res. 2001, 408-414.
44. Liu J., Ormsby A., Oja-Tebbe N., Pagano P.J. Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ. Res. 2004, 95:587-594.
45. Morris C.D., Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U. S., Preventive Services Task Force. Ann. Intern. Med. 2003, 56-70.
46. Touyz R.M. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?. Hypertension 2004, 44:248-252.
47. Radovits T., Zotkina J., Lin L.N., Bömicke T., Arif R., et al. Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. Exp. Biol. Med. (Maywood) 2007, 232:1204-1212.
48. Radnai B., Antus C., Racz B., Engelmann P., Priber J.K., et al. Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation. Mol. Cancer 2012, 11:34.
49. Pacher P., Mabley J.G., Soriano F.G., Liaudet L., Szabó C. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Int. J. Mol. Med. 2002, 9:659-664.
50. Sandhu S.K., Yap T.A., de Bono J.S. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr. Drug Targets 2011, 12:2034-2044.
51. Genovese T., Cuzzocrea S. Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets. Curr. Med. Chem. 2008, 15:477-487.
52. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 2002, 90:E58-E65.
53. Zhou H.Z., Swanson R.A., Simonis U., Ma X., Cecchini G., et al. Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H714-H723.
54. Kwon S.H., Hong S.I., Kim J.A., Jung Y.H., Kim S.Y., et al. The neuroprotective effects of Lonicera japonica THUNB. against hydrogen peroxide-induced apoptosis via phosphorylation of MAPKs and PI3K/Akt in SH-SY5Y cells. Food Chem. Toxicol. 2011, 49:1011-1019.
55. Joza N., Susin S.A., Daugas E., Stanford W.L., Cho S.K., et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001, 410:549-554.
56. Veto S., Acs P., Bauer J., Lassmann H., Berente Z., et al. Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 2010, 133:822-834.
57. Autieri M.V., Kelemen S.E., Wendt K.W. AIF-1 is an actin-polymerizing and Rac1-activating protein that promotes vascular smooth muscle cell migration. Circ. Res. 2003, 92:1107-1114.
58. Wang Y., Kim N.S., Haince J.F., Kang H.C., David K.K., et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci. Signal. 2011, 4:ra20.
59. Racz B., Hanto K., Tapodi A., Solti I., Kalman N., Jakus P., et al. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation. Free Radic. Biol. Med. 2010, 49:1978-1988.
60. Chung A.C., Zhang H., Kong Y.Z., Tan J.J., Huang X.R., Kopp J.B., et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J. Am. Soc. Nephrol. 2010, 21:249-260.
61. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ. Res. 2006, 98:1032-1039.
62. Zamo F.S., Barauna V.G., Chiavegatto S., Irigoyen M.C., Oliveira E.M. The renin-angiotensin system is modulated by swimming training depending on the age of spontaneously hypertensive rats. Life Sci. 2011, 89:93-99.
63. Ma Y., Chen B., Liu D., Yang Y., Xiong Z., et al. MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway. Biochem. Pharmacol. 2011, 81:1228-1236.
64. Lan H.Y. Smad7 as a therapeutic agent for chronic kidney diseases. Front. Biosci. 2008, 13:4984-4992.
65. Paravicini T.M., Touyz R.M. Redox signaling in hypertension. Cardiovasc. Res. 2006, 71:247-258.